Has Henry Holt, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,764 in general payments to Henry Holt, MD across 38 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Henry Holt, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Henry Holt, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Henry Holt, MD

Retina Specialist · Wilmington, NCNPI 1417237884

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,231 of the $1,764 with a category attached, or 69.8%. 12 manufacturers reported payments, led by Notal Vision, Inc. at 30.2% of the total. Reporting peaked in 2022 at $758 and has fallen 70.5% since, to $223 in 2025. That places this record below the midpoint for retina specialist clinicians in NC, where the typical reported total is $3,753.

$1,764in general payments, 2019–2025

Across 38 payments — averaging $46.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Notal Vision, Inc.$533
Bausch & Lomb Americas Inc.$271
Bausch & Lomb, A Division Of Bausch Health US, LLC$207
Astellas Pharma US Inc$176
Regeneron Healthcare Solutions, Inc.$173
Mallinckrodt Hospital Products Inc.$153
plus $252 from 6 others

$930in research payments, 2019–2025

Across 24 payments — averaging $38.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Notal Vision, Inc.$930

What the payments were for

Speaking & faculty fees$53330%
Food & beverage$1,23170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Notal Vision, Inc.	4	$533
Bausch & Lomb Americas Inc.	4	$271
Bausch & Lomb, A Division Of Bausch Health US, LLC	2	$207
Astellas Pharma US Inc	2	$176
Regeneron Healthcare Solutions, Inc.	8	$173
Mallinckrodt Hospital Products Inc.	5	$153
Genentech USA, Inc.	7	$131
Harrow Eye, LLC	1	$39
AbbVie	2	$28
ANI Pharmaceuticals, Inc.	1	$21
Topcon Healthcare, Inc.	1	$19
Novartis	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INFUSE$211
Izervay$147
MIEBO$120
XIIDRA$120
BIOTRUE$104
ULTRA$104
ENVISTA$102
STELLARIS$102

How this compares

$1,764 in reported general payments places this provider in the 35th percentile of 34 retina specialist providers in North Carolina.

See all retina specialist providers in North Carolina →

Medicare billing

Part B allowed, 2024

$3,832,812

Medicare patients

1,213

Services billed

59,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	194	$12,050
Mycophenolate Mofetil	60	$5,597
Atropine Sulfate	71	$2,775
Brimonidine Tartrate	67	$2,752
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	138	$2,205
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	103	$1,364
MethotrexateMethotrexate Sodium	32	$639
Timolol Maleate	29	$634
Prednisone	44	$498
MoxifloxacinMoxifloxacin Hcl	20	$378
Dorzolamide Hcl	15	$179
Latanoprost	20	$120

Paid to pharmacies, not to this prescriber.

Other retina specialist in Wilmington

Igor WestraWilmington$3K
Kevin BrayWilmington$1K
Eleonora LadDurham$331K
Daniel BennettRaleigh$126K
Michael AllinghamDurham$63K
Raynor CaseyRaleigh$34K
Sachin MudvariRaleigh$33K
John ThordsenRaleigh$33K
John DennyRaleigh$31K
William BridgesAsheville$13K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →